Homology Medicines is a genetic medicines company. Co.'s proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs), to deliver single administration genetic medicines in vivo either through gene therapy or nuclease-free gene editing across a range of genetic disorders. The properties of Co.'s proprietary suite of AAVHSCs enable it to focus on a method of gene editing called gene integration, through the replacement of an entire diseased gene in the genome with a whole functional copy by harnessing the naturally occurring deoxyribonucleic acid, repair process of homologous recombination. The FIXX stock yearly return is shown above.
The yearly return on the FIXX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the FIXX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|